Objective-Plasma levels of high density lipoprotein (HDL) cholesterol and apolipoprotein (apo)A-I are decreased in inflammatory states. Secretory phospholipase A 2 (sPLA 2 ), an acute-phase protein, may play a key role in the pathophysiology of this phenomenon. Methods and Results-To investigate the effects of sPLA 2 on human-like HDL particles in vivo, we generated transgenic mice overexpressing human apoA-I and human sPLA 2 (apoA-I/sPLA 2 mice). Compared with apoA-I mice, apoA-I/ sPLA 2 mice had significantly lower plasma levels of phospholipids, HDL cholesterol, and apoA-I (each PϽ0.01). HDL from apoA-I/sPLA 2 mice was significantly depleted in phospholipids and cholesteryl esters (each PϽ0.001) but was enriched in protein and triglycerides (each PϽ0.001). As assessed by gel filtration and nondenaturing gel electrophoresis, sPLA 2 overexpression in apoA-I mice resulted in a dramatic shift of the HDL particle size toward smaller particles. Furthermore, virtually all plasma sPLA 2 in apoA-I/sPLA 2 mice was found in association with the HDL fraction. The acute-phase response was induced in apoA-I/sPLA 2 double-transgenic and apoA-I single-transgenic mice by intraperitoneal lipopolysaccharide (LPS) injection. Plasma sPLA 2 was significantly increased after LPS injection in apoA-I/ sPLA 2 mice. Twelve hours after LPS administration, plasma total cholesterol, HDL cholesterol, apoA-I, and phospholipids were unchanged in apoA-I transgenic control mice but had decreased significantly in the apoA-I/sPLA 2 mice (Ϫ57%, Ϫ62%, and Ϫ54%, Ϫ61%, respectively; each PϽ0.001). Both groups of mice had increased plasma levels of serum amyloid A (SAA) in response to LPS. To test the hypothesis that SAA may be an in vivo activator of sPLA 2 , we specifically overexpressed SAA in apoA-I/sPLA 2 mice by means of liver-directed gene transfer. Despite high plasma levels of SAA, plasma lipid and lipoprotein profiles were not different than those in control mice. Conclusions-These results in a mouse model of human-like HDL indicate that sPLA 2 expression significantly influences HDL particle size and composition and demonstrate that an induction of sPLA 2 is required for the decrease in plasma HDL cholesterol in response to inflammatory stimuli in mice and that this effect is independent of SAA. (Arterioscler Thromb Vasc Biol. 2002;22:1213-1218.)
P lasma levels of HDL cholesterol and its major apolipoprotein, apoA-I, show a strong inverse association with the risk of atherosclerotic cardiovascular disease. 1,2 HDL cholesterol and apoA-I levels are decreased in acute as well as chronic inflammatory states. 3, 4 The pathophysiological nature of this observation is incompletely understood, but patients with chronic inflammatory diseases, such as rheumatoid arthritis, are at an increased risk of atherosclerotic cardiovascular disease. 5 These data underline the importance of providing a better understanding of the regulation of HDL metabolism in inflammatory states. In addition, atherosclerosis itself has been recognized as a local inflammatory condition of the vessel wall, 6 and markers of inflammation, such as plasma levels of C-reactive protein, serum amyloid A (SAA), and soluble intercellular adhesion molecule-1, have been demonstrated as predictors of future coronary events. 7
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Group IIA secretory phospholipase A 2 (sPLA 2 ) is an acute-phase protein that exhibits solely phospholipase activity. It is synthesized by many different tissues, including vascular smooth muscle cells, neutrophils, platelets, and liver. 8 -10 sPLA 2 expression is upregulated, and plasma levels increase significantly during the acute-phase response (APR) and are also elevated in chronic inflammatory states. [11] [12] [13] A recent study showed that plasma levels of sPLA 2 are also predictive of angiographic coronary disease. 14 Transgenic overexpression of human sPLA 2 in mice accelerates atherogenesis. 15 We previously demonstrated that sPLA 2 transgenic mice have increased catabolism of HDL apolipoproteins and HDL cholesteryl esters, resulting in decreased HDL cholesterol plasma levels. 16 Another acute-phase protein that traditionally has been implicated with changes in HDL cholesterol in acute and chronic inflammatory states is the SAA protein. 3, 17, 18 Surprisingly, overexpression of acute-phase SAA by means of somatic gene transfer had no effect on plasma HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. 19 However, one property of acute-phase SAA might be to activate sPLA 2 in vitro. 20 In our previous study, we overexpressed SAA in human apoA-I transgenic mice on a C57BL/6 genetic background. 19 Mice on this background lack the endogenous mouse sPLA 2 enzyme because of a frameshift mutation in the mouse sPLA 2 gene. 21 Therefore, the lack of reduction of HDL cholesterol levels with overexpression of SAA could be due to the lack of endogenous sPLA 2 .
The purpose of the present study was to use human apoA-I/human sPLA 2 double-transgenic mice to directly test the hypothesis that upregulation of sPLA 2 during acute inflammation is required to mediate the decrease in HDL cholesterol and apoA-I levels. In addition, we used this novel double-transgenic mouse model to determine whether acutephase SAA might be an activator of sPLA 2 in vivo. Our results demonstrate that sPLA 2 expression confers susceptibility to decreased HDL cholesterol and apoA-I plasma levels in response to inflammation. However, high-level expression of human acute-phase SAA by gene transfer into apoA-I/ sPLA 2 mice did not alter plasma lipid or lipoprotein levels compared with those levels in control adenovirus-injected mice. These results indicate that (1) sPLA 2 is of major importance for the decrease in plasma HDL levels in inflammatory states, and (2) SAA is not an activator of sPLA 2 in vivo.
Methods

Animal Studies
The generation of human group II sPLA 2 transgenic mice has been described previously. 22 The sPLA 2 transgenic line has been backcrossed to the C57BL/6 background for 12 backcrosses. sPLA 2 transgenic mice were crossbred with human apoA-I transgenic mice on the C57BL/6 genetic background (Jackson Laboratory, Bar Harbor, Me). Human apoA-I single-transgenic littermates from this breeding served as controls for experiments with the apoA-I/sPLA 2 double-transgenic mice. The animals were caged in animal rooms with alternating 12-hour periods of light (from 7:00 AM to 7:00 PM) and dark (from 7:00 PM to 7:00 AM), with ad libitum access to water and mouse chow diet.
For induction of the APR, mice were injected intraperitoneally with 75 g lipopolysaccharide (LPS, Escherichia coli 0111:B4, DIFCO Laboratories) or sterile saline, and blood was obtained before injection and 12 hours after injection. 19 
Plasma Lipid and Lipoprotein Analysis
Mice were bled from the retro-orbital plexus after a 4-hour fast with the use of heparinized capillary tubes. Blood was drawn into tubes containing 2 mmol/L EDTA, 0.2% NaN 3 , and 1 mmol/L benzamidine. Aliquots were stored at Ϫ20°C until analysis. Plasma total cholesterol, HDL cholesterol, triglyceride, phospholipid, and human apoA-I levels were measured on a Cobas Fara (Roche Diagnostics Systems Inc) with the use of Sigma Diagnostics reagents (Sigma Diagnostics).
For the analysis of HDL composition, HDL was isolated from 100 L mouse plasma by tabletop sequential ultracentrifugation (1.063ϽdensityϽ1.25). 16 After dialysis, concentrations of protein, total and free cholesterol, triglycerides, and phospholipids were determined with commercially available assays modified for microtiter plates (Wako Pure Chemical Industries, Ltd). Values for the esterified cholesterol were calculated by subtracting free cholesterol values from total cholesterol values.
Gel Filtration Analysis
Pooled plasma samples from mice of the same experimental group were subjected to fast protein liquid chromatography (FPLC) gel filtration by using 2 Superose 6 columns (Pharmacia LKB Biotechnology) as described. 16 Samples were chromatographed at a flow rate of 0.5 mL/min, and fractions of 500 L each were collected. Individual fractions were assayed for cholesterol concentrations by using commercially available assay kits (Wako Pure Chemical Industries, Ltd).
Construction of Recombinant Adenoviruses
The construction of the recombinant adenovirus expressing human acute-phase SAA1 (AdhSAA) has been described previously. 19 To control for virus-related effects on lipoprotein metabolism, an adenovirus lacking a transgene was used (AdE1⌬). 23 Viruses were grown and purified as previously described 19 and stored in PBS with 10% glycerol at Ϫ80°C until use.
Western Blotting
Western blot analysis to identify mice transgenic for human group II sPLA 2 was performed as previously described. 16 To study the association of sPLA 2 with different lipoprotein subclasses, 42 L of the indicated FPLC fractions was mixed with 6ϫ nonreducing sample buffer, electrophoresed, and detected as described above. To assess the distribution of human apoA-I across different lipoprotein subclasses, 7 L each of 3 consecutive FPLC fractions was pooled, mixed with 4ϫ reducing sample buffer, electrophoresed on a 15% SDS-PAGE, and electroblotted to nitrocellulose. As a first antibody, a monoclonal mouse anti-human apoA-I antibody (kindly provided by Dr David Usher, University of Delaware, Newark) was used as the primary antibody, followed by the appropriate secondary antibody. Western blot for SAA was performed as described. 19 
Statistical Analysis
Values are presented as meanϮSD unless otherwise indicated.
Results were analyzed by ANOVA and Student t test with the use of GraphPad Prism Software. Statistical significance for all comparisons was assigned at PϽ0.05.
Results
Human sPLA 2 Overexpression Reduces HDL Cholesterol and ApoA-I Levels in Human ApoA-I Transgenic Mice
Plasma lipid and apolipoprotein levels in apoA-I/sPLA 2 double-transgenic mice and their apoA-I transgenic littermates are summarized in the Table. Plasma triglyceride and non-HDL cholesterol levels did not differ between the 2 groups of mice. Plasma levels of phospholipids were significantly decreased by 23% (PϽ0.001), total plasma cholesterol was decreased by 27% (PϽ0.01), HDL cholesterol was decreased by 38% (PϽ0.001), and apoA-I was decreased by 37% (PϽ0.001) in apoA-I/sPLA 2 double-transgenic mice compared with control apoA-I transgenic mice.
Overexpression of sPLA 2 Generates Smaller HDL Particles of Altered Composition in Human ApoA-I Transgenic Mice
To assess changes in specific lipoprotein classes, we performed FPLC gel filtration on pooled plasma samples from apoA-I/sPLA 2 double-transgenic mice and their apoA-I transgenic littermates ( Figure 1A ). There were no obvious differences in the VLDL and LDL cholesterol fractions. However, overexpression of sPLA 2 in human apoA-I transgenic mice resulted in a major change in the HDL cholesterol peak, with a marked reduction of large HDL particles (fractions 24 to 32) and a shift toward smaller HDL particles. Western blot analysis for human apoA-I in the FPLC fractions ( Figure 1B ) demonstrated a shift in human apoA-I distribution toward smaller particles, consistent with the findings observed for HDL cholesterol in the fractions. In addition, nondenaturing gel electrophoresis and gel filtration of ultracentrifugally isolated HDL confirmed that sPLA 2 expression results in a marked loss of larger HDL particles in apoA-I transgenic mice (please see online Figure IA through IC, available at http://www.ahajournals.org). Thus, by 3 different analytical methods, HDL in apoA-I/sPLA 2 double-transgenic mice is considerably smaller than that in human apoA-I singletransgenic mice. Compositional analysis of HDL particles isolated by ultracentrifugation (please see online Table I , available at http:// www.ahajournals.org) showed that HDL from the apoA-I/ sPLA 2 double-transgenic mice had a significantly greater protein and triglyceride content compared with HDL from control mice (each PϽ0.001) and significantly less cholesteryl ester (PϽ0.001) and phospholipids (PϽ0.001). The relative proportion of free cholesterol remained unchanged between both groups of experimental mice.
Human sPLA 2 Is Selectively Associated With the HDL Fraction in Human ApoA-I Transgenic Mice
Next, we investigated whether human sPLA 2 was associated with the HDL fraction and performed Western blot analysis for sPLA 2 on FPLC fractions representing specific lipoprotein fractions ( Figure 2) . In VLDL and LDL as well as in the lipoprotein-free fraction, no immunoreactive human sPLA 2 protein was detectable. Virtually all plasma human sPLA 2 protein was associated with HDL fractions, especially with the fractions containing larger HDL particles.
Acute Inflammation Alters HDL Metabolism in Human ApoA-I/sPLA 2 Double-Transgenic but Not Human ApoA-I Single-Transgenic Mice
We hypothesized that the presence of the human sPLA 2 transgene under the control of its own promoter would confer responsiveness of human apoA-I transgenic mice to endotoxin regarding the effects on HDL metabolism. Plasma phospholipids, total cholesterol, HDL cholesterol, and apoA-I levels in both groups of saline-injected mice did not change significantly 12 hours after injection compared with baseline values. Twelve hours after induction of the APR by intraperitoneal injection of LPS in apoA-I single-transgenic mice, plasma phospholipids, total cholesterol, HDL cholesterol, and apoA-I levels in apoA-I single-transgenic mice were not significantly changed compared with baseline values ( Figure  3 ), consistent with our previous report. 19 In contrast, 12 hours after LPS injection in mice overexpressing sPLA 2 , plasma levels of phospholipids decreased by 61% (231Ϯ39 versus 90Ϯ18 mg/dL, PϽ0.001), total cholesterol decreased by 57% (128Ϯ16 versus 55Ϯ7 mg/dL, PϽ0.001), HDL cholesterol decreased by 62% (90Ϯ18 versus 34Ϯ13 mg/dL, PϽ0.001), and apoA-I levels decreased by 54% (254Ϯ34 versus 117Ϯ29 mg/dL, PϽ0.001; Figure 3 ). The experimental mice were not fasted throughout the experiment, making the interpretation of the changes in plasma triglyceride levels more difficult. However, in saline-injected mice, plasma triglyceride levels did not change significantly. In LPS-injected apoA-I transgenic mice, plasma triglycerides increased by 61%, whereas in apoA-I/sPLA 2 double-transgenic mice, plasma triglyceride levels were decreased by 45Ϯ27%. The FPLC analysis on this experiment is shown in online Figure II , available at http://www.ahajournals.org.
Plasma Lipid and Lipoprotein Profiles in Human ApoA-I/Human sPLA 2 Double Transgenic Mice and Human ApoA-I Single Transgenic Littermates
Effects of Endotoxin on sPLA 2 and SAA Expression
As assessed by Western blot analysis, induction of the APR resulted in a significant upregulation of sPLA 2 expression in apoA-I/sPLA 2 double-transgenic mice (please see online Figure IIIA , available at http://www.ahajournals.org). SAA was also induced in all LPS-injected mice to a similar extent (please see online Figure IIIB ).
SAA Overexpression Does Not Alter Lipid Levels or Lipoprotein Profiles in ApoA-I/sPLA 2 Double-Transgenic Mice
To test the hypothesis that SAA could be an activator of sPLA 2 in vivo, as suggested by in vitro studies, 20 we overexpressed acute-phase SAA by means of liver-directed adenoviral gene transfer in apoA-I/sPLA 2 double-transgenic mice. Two groups of control apoA-I/sPLA 2 double-transgenic mice were injected with either a control adenoviral vector or saline. Neither control adenovirus (Ad.E1⌬) nor saline injection induced SAA protein expression (data not shown), consistent with our previous findings. 19 If SAA acts as an activator of sPLA 2 in vivo, then the high levels of SAA in the apoA-I/sPLA 2 double-transgenic mice might be expected to result in further sPLA 2 activation, with further reduction in phospholipids, HDL cholesterol, and apoA-I. In contrast to our hypothesis, high-level expression of SAA was no different from control vector in its effects on phospholipids, total cholesterol, HDL cholesterol, and apoA-I (Figure 4 ). Gel filtration analysis on pooled plasma samples on day 3 after injection of AdhSAA, control virus, or PBS showed that compared with baseline, expression of human SAA did not result in a specific change in cholesterol distribution among lipoprotein fractions or a change in HDL size (data not shown). These findings extend our previous observation that high-level SAA expression had no effect in reducing HDL cholesterol levels in mice lacking endogenous sPLA 2 19 and indicate that even in the presence of sPLA 2 , SAA expression has no effect on HDL metabolism.
Discussion
In the present study, we demonstrate that human sPLA 2 overexpression had profound effects on human-like HDL in human apoA-I transgenic mice. ApoA-I/sPLA 2 doubletransgenic mice had lower plasma phospholipid, HDL cholesterol, and apoA-I levels, an altered HDL composition, and a major shift in HDL size toward smaller HDL particles. Furthermore, by Western blot analysis, we demonstrated that virtually all of the plasma human sPLA 2 was associated with the HDL fraction. We also demonstrated that expression of the human sPLA 2 transgene confers substantial responsiveness to endotoxin regarding plasma levels of HDL cholesterol, apoA-I, and phospholipids in human apoA-I transgenic mice. Finally, we show that high-level expression of SAA alone in apoA-I/sPLA 2 double-transgenic mice had no effects on plasma HDL cholesterol, apoA-I, or phospholipids compared with a control adenovirus. These results extend previous observations and strongly support the concept that the human group IIA sPLA 2 is capable of hydrolyzing phospholipids in human-like HDL in vivo, thereby influencing its metabolism, and that SAA does not serve as an activator of sPLA 2 in vivo. sPLA 2 is an acute-phase protein, and sPLA 2 plasma levels increase dramatically during acute inflammatory conditions 12 and are also found to be elevated in chronic inflammatory diseases. 13 In a previous study, we demonstrated that transgenic overexpression of sPLA 2 in wild-type mice results in increased catabolism of HDL cholesteryl esters and apoA-I, suggesting that sPLA 2 may be a key enzyme responsible for the decreased HDL plasma levels in inflammatory conditions. 16 For the present study, we chose human apoA-I transgenic mice on a C57BL/6 background to assess in detail the effects of sPLA 2 overexpression in an accepted animal model with greater relevance for human HDL metabolism. 24, 25 In fact, overexpression of human sPLA 2 in wildtype C57BL/6 mice revealed a decrease in plasma HDL cholesterol by 28%, 16 whereas on the background of human apoA-I transgenic mice in the present study, the decrease was almost 40%.
Metabolic studies of HDL in humans revealed that variations in HDL cholesterol and apoA-I plasma levels are due largely to changes in the rate of apoA-I catabolism, not synthesis. 26 -28 The size of HDL particles has been recognized as a major determinant of the rate of catabolism, with smaller particles having faster catabolism. 26 In human apoA-I transgenic mice, HDL is found to be mainly distributed between 2 major subclasses resembling the HDL distribution in humans. 24 sPLA 2 overexpression resulted in a dramatic reduction, especially of the subclass containing the larger HDL particles. Therefore, generation of smaller HDL particles in sPLA 2 transgenic mice likely contributes to the increased HDL catabolic rate that we demonstrated in sPLA 2 transgenic mice on a wild-type background. 16 Human apoA-I single-transgenic mice on the C57BL/6 genetic background that lack the endogenous mouse sPLA 2 enzyme 21 are resistant to an LPS-induced decrease in plasma HDL. 19, 29 The sPLA 2 transgenic mice used in the present study were generated by using the endogenous promoter elements necessary to confer upregulation of the sPLA 2 gene in response to inflammation. As expected, inflammatory stimuli, such as administration of Staphylococcus aureus, 30 to these human sPLA 2 transgenic mice resulted in a severalfold induction of sPLA 2 expression. Therefore, we hypothesized that if the sPLA 2 were responsible for the reduction in HDL cholesterol levels, then upregulation by an inflammatory stimulus should result in further changes in HDL. We injected mice with LPS and, by Western blot analysis, showed that 12 hours after LPS administration, plasma levels of sPLA 2 increased significantly in apoA-I/sPLA 2 double-transgenic mice. In contrast to human apoA-I single transgenic mice, in which there were no effects on plasma lipid levels, injection of LPS in apoA-I/sPLA 2 double-transgenic mice resulted in marked further reductions in phospholipids, HDL cholesterol, and apoA-I. This result confirms that introduction of an sPLA 2 transgene in mice lacking sPLA 2 confers responsiveness to LPS with regard to HDL metabolism.
SAA has been proposed to be a factor responsible for the decrease of HDL cholesterol during the APR. Plasma SAA is found in association with HDL particles and has been shown in vitro to be capable of displacing apoA-I from the HDL particle. 31 We previously demonstrated that high plasma levels of SAA in the absence of an APR had no significant effect on plasma HDL cholesterol levels or HDL size distribution in human apoA-I transgenic mice. 19 However, these studies were performed in mice lacking sPLA 2 , and an in vitro study suggested that SAA might be an activator of sPLA 2 . 20 To test the hypothesis that SAA may influence HDL metabolism by enhancement of sPLA 2 activity, we used liver- directed gene transfer to express high levels of SAA in apoA-I/sPLA 2 double-transgenic mice. To exclude speciesspecific effects, we chose the human SAA transgene to test for a potential activating action on the human sPLA 2 in our mouse model. Despite the presence of sPLA 2 , the expression of SAA had no effect on HDL or apoA-I levels or on the size distribution of the HDL particles.
In summary, we demonstrate that sPLA 2 expression results in decreased plasma levels of phospholipids, HDL cholesterol, and apoA-I, in compositional changes of HDL, and in the generation of smaller HDL particles. sPLA 2 expression confers exquisite sensitivity of human apoA-I transgenic mice to endotoxin regarding changes in HDL metabolism. These alterations might be beneficial in relation to host defense toward bacterial pathogens but are conceivably proatherogenic in the case of chronic inflammation. These studies have implications for the understanding of HDL pathophysiology in acute and chronic inflammatory states and suggest that sPLA 2 would be an attractive target for inhibition, thus providing a strategy for raising plasma HDL levels in patients with chronic inflammation, including atherosclerotic disease itself.
